Form 4: Fulgent Genetics Director Receives Equity Grant

Director Michael Nohaile acquired 5,558 restricted stock units and 8,426 stock options as part of an equity compensation package.

Summary

• Director Michael Nohaile was granted 5,558 restricted stock units (RSUs) on May 14, 2026.
• The director also received a stock option grant for 8,426 shares with an exercise price of $16.19.
• Both the RSUs and the stock options are subject to a four-year vesting schedule.
• Following these transactions, the director's total direct beneficial ownership of common stock increased to 24,578 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment for investors.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standard four-year vesting schedule encourages long-term retention and service.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Continued service requirements for vesting may be impacted by future changes in board composition.
• Market volatility could affect the future value of the granted options and RSUs.

Future Outlook

The equity grants are subject to a four-year vesting period, with 25% vesting after one year and the remainder vesting quarterly over the subsequent three years, contingent upon continued service.

Management Comments

• The transactions were executed as part of standard director compensation arrangements.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology and genetics sector to ensure leadership alignment with corporate performance and long-term strategic goals.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard corporate governance practices for board members in the U.S. healthcare and biotech industries.
• The use of both RSUs and stock options is a common compensation structure for directors at mid-cap growth companies.

Corporate Governance

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of the first tranche of equity on May 14, 2027.

Key Dates

Keywords

Fulgent Genetics, FLGT, Form 4, Insider Trading, Equity Compensation, Director Compensation